ClinicalTrials.gg
RecruitingNCT07446322Updated Nov 5, 2026

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

A Phase 2 interventional study of Bevacizumab and FOLFIRI in Ras-mutated Metastatic Colorectal Cancer, mCRC and MSS Metastatic Colorectal Cancer, sponsored by Oncolytics Biotech. Recruiting at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Oncolytics Biotech · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 5, 2026Site recruiting status changed4 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.

Planned enrollment
115th of 224
60 · median 63
Started
2026
with 12 others
Phase 2
133 of 230
31 open now
Primary completion
2027-08
later than 36 of 60 live
Registered
224th of 230
by date

Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is the 115th largest by planned enrollment of the 224 interventional ones that give a count, is one of 13 that started in 2026, is one of 133 in phase 2, reaches primary completion later than 36 of the 60 other live ones, and was the 224th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

43 more — sign in →

By country, each count listing its studies:

All 49 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies testing bevacizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.

Read the detailed description

Approximately 60 patients will be randomized 1:1 to the following study arms:

  • Arm A: FOLFIRI + bevacizumab + pelareorep
  • Arm B: FOLFIRI + bevacizumab The primary endpoint is ORR as assessed by the investigator per RECIST 1.1. OS, PFS, and assessment of the safety and tolerability of the study treatment combinations are secondary endpoints. The primary endpoint analysis will be performed after all patients have had at least one tumor assessment following initiation of study treatment or have progressed. The secondary endpoint analyses will take place at EOS.
03

Conditions studied

  • Ras-mutated Metastatic Colorectal Cancer
  • mCRC
  • MSS Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed cancer of the colon or rectum with documented
  • per v. 1.1
  • Not candidates for curative surgery or curative radiation
  • Progressed on, or been intolerant to, a , oxaliplatin-based chemotherapy regimen in the metastatic setting or within 6 months of completing adjuvant oxaliplatin
  • Considered medically eligible to receive standard of care (SOC) FOLFIRI with bevacizumab
  • Non-microsatellite instability high or non-deficient mismatch repair (non-MSI-H/non dMMR) tumor status per a standard local testing method
  • Tumor confirmed to harbor a known RAS mutation per a standard local testing method
  • performance status of 0 or 1
  • Patients must have adequate hematological, renal, and hepatic function
  • Female patients of must have a negative pregnancy test
  • of at least 6 months

Exclusion criteria

Exclusion Criteria:

  • Undergone systemic chemotherapy, radiotherapy, or surgery, \<4 weeks before study treatment
  • Ongoing AEs of Grade ≥2 that are related to anti-cancer treatment
  • Prior treatment with irinotecan
  • Symptomatic
  • Active disease
  • Receiving or myelosuppressive medications
  • Active, uncontrolled infections
  • Known infection or active or C that requires anti-viral treatment
  • History of another primary cancer within the last 3 years except for non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ
  • History of allergy or known to any of the study drugs, study drug classes,
  • Uncontrolled or severe cardiac disease
  • Received any vaccine within 28 days prior to first study treatment
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Arm A

    Drug: Bevacizumab · Drug: FOLFIRI · Drug: Pelareorep

  • Experimental
    Arm B

    Drug: Bevacizumab · Drug: FOLFIRI

Interventions

  • Bevacizumab (5 mg/kg) IV infusion

    Also known as: Avastin

  • DrugFOLFIRI

    irinotecan (180mg/m2), leucovorin 400 mg/m2 ± 5-FU (400 mg/m2) IV infusion

  • pelareorep 4.5 x 10\^10 TCID50 IV infusion

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Proportion of patients with complete response \[CR\], partial response \[PR\] assessed by the investigators and/or central reader according to RECIST v1.1

    Time frame: At week 8

Secondary outcomes

  1. Overall Survival (OS) -

    OS defined as the time from date of randomization to death from any cause

    Time frame: From the date of randomization through long term follow up at two years

  2. Progression Free Survival (PFS)

    Time from randomization to the date of investigator-determined objective progression (according to RECIST 1.1) or death from any cause, whichever occurs first.

    Time frame: From randomization to objective progression or death from any cause, whichever occurs first, up to two years

  3. Disease Control Rate (DCR)

    Overall DCR, defined as the number of patients with a best overall response of CR, PR, or SD according to RECIST v. 1.1

    Time frame: From randomization to disease progression or death from any cause, whichever occurs first, up to two years

  4. Duration of Response (DOR)

    Time from documentation of the first CR or PR to the time of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death.

    Time frame: From randomization to disease progression or death from any cause, whichever occurs first, up to two years

07

Study locations

20 of 20 sites recruiting
08

Timeline

7 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2027, 16 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 16 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 3, 2026
StartActual
Apr 30, 2026
Primary completionEst.
Aug 30, 2027
CompletionEst.
Apr 30, 2030
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Moffitt Cancer Center · Tampa, United StatesNot yet recruiting→Recruiting
  • Community Health Network · Indianapolis, United StatesNot yet recruiting→Recruiting
Show 4 added (4 United States)
  • Northwestern Memorial Hospital · Chicago, United States
  • University of Cincinnati Medical Center · Cincinnati, United States
  • Ohio State University · Colombus, United States
  • The University of Texas MD Anderson Cancer Center · Houston, United States
across 4 updates, Sep 25, 2026 – Nov 5, 2026
Site contacts
Changed at 6 sites. See the sites
Show 6 sites
  • Central Alabama Research · Homewood, United StatesContact none listed→•••1907
  • Gabrail Cancer Center · Canton, United StatesContact c•••@gabrailcancercenter.com→r•••@gabrailcancercenter.comContact none listed→•••8231Contact added r•••@gabrailcancercenter.com · •••3345
  • Community Health Network · Indianapolis, United StatesContact added M•••@ecommunity.com · •••4300
  • Washington University School of Medicine · St Louis, United StatesContact l•••@wustl.edu→j•••@wustl.edu · •••2582
  • Northwestern Memorial Hospital · Chicago, United StatesContact s•••@northwestern.edu→c•••@northwestern.edu
  • Emory Winship Cancer Institute · Atlanta, United StatesContact added k•••@emory.edu · •••1278
across 5 updates, Sep 28, 2026 – Oct 27, 2026
Show all 7 updates
  1. Nov 5, 2026
    1 site added
    Show site
    • The University of Texas MD Anderson Cancer Center · Houston, United States
  2. Oct 27, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Emory Winship Cancer Institute · Atlanta, United StatesContact added k•••@emory.edu · •••1278
  3. Oct 19, 2026
    2 sites added
    Show 2 added (2 United States)
    • University of Cincinnati Medical Center · Cincinnati, United States
    • Ohio State University · Colombus, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Northwestern Memorial Hospital · Chicago, United StatesContact s•••@northwestern.edu→c•••@northwestern.edu
  4. Oct 6, 2026
    Community Health Network is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Washington University School of Medicine · St Louis, United StatesContact l•••@wustl.edu→j•••@wustl.edu · •••2582
  5. Sep 29, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Community Health Network · Indianapolis, United StatesContact added M•••@ecommunity.com · •••4300
  6. Sep 28, 2026
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Central Alabama Research · Homewood, United StatesContact none listed→•••1907
    • Gabrail Cancer Center · Canton, United StatesContact c•••@gabrailcancercenter.com→r•••@gabrailcancercenter.comContact none listed→•••8231Contact added r•••@gabrailcancercenter.com · •••3345
  7. Sep 25, 2026
    1 site added. Moffitt Cancer Center is now Recruiting
    Show site
    • Northwestern Memorial Hospital · Chicago, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07446322
Lead sponsor
Oncolytics Biotech
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Apr 30, 2026
Primary completion
Aug 30, 2027 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Nov 5, 2026

Study contacts

Name: Reference Study ID Number: REO 033
Contact
REO-033@oncolytics.com
+1 (858) 247-7829

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion